EX-99.2O 3 a4q20118-kexhibit992o.htm FINANCIALS 4Q 2011 8-K Exhibit 99.2O
Exhibit 99.2O


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
FOURTH QUARTER
 
2011
 
2010
 
Percent

 
 
 
Percent

 
 
 
Percent

 
Increase

 
Amount

 
to Sales

 
Amount

 
to Sales

 
(Decrease)

Sales to customers
$
16,255

 
100.0

 
$
15,644

 
100.0

 
3.9

Cost of products sold
5,338

 
32.8

 
5,040

 
32.2

 
5.9

Selling, marketing and administrative expenses
5,458

 
33.6

 
5,180

 
33.1

 
5.4

Research and development expense
2,155

 
13.3

 
1,982

 
12.7

 
8.7

Interest (income)expense, net
148

 
0.9

 
114

 
0.7

 
 
Other (income)expense, net
2,858

 
17.6

 
1,100

 
7.1

 
 
Restructuring (income)expense, net
(20
)
 
(0.1
)
 

 

 
 
Earnings before provision for taxes on income
318

 
1.9

 
2,228

 
14.2

 
(85.7
)
Provision for taxes on income
100

 
0.6

 
286

 
1.8

 
(65.0
)
Net earnings
$
218

 
1.3

 
$
1,942

 
12.4

 
(88.8
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
$
0.08

 
 
 
$
0.70

 
 
 
(88.6
)
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,768.9

 
 
 
2,781.6

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
31.4
%
 
 
 
12.8
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings(A)
 
 
 
 
 
 
 
 
 
     Earnings before provision for taxes on income
$
3,657

(1)
22.5

 
$
3,451

(1)
22.1

 
6.0

     Net earnings
$
3,129

(1)
19.2

 
$
2,864

(1)
18.3

 
9.3

     Net earnings per share (Diluted)
$
1.13

(1)
 
 
$
1.03

(1)
 
 
9.7

     Effective tax rate
14.4
%
 
 
 
17.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 






Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
TWELVE MONTHS
 
2011
 
2010
 
Percent

 
 
 
Percent

 
 
 
Percent

 
Increase

 
Amount

 
to Sales

 
Amount

 
to Sales

 
(Decrease)

Sales to customers
$
65,030

 
100.0

 
$
61,587

 
100.0

 
5.6

Cost of products sold
20,360

 
31.3

 
18,792

 
30.5

 
8.3

Selling, marketing and administrative expenses
20,969

 
32.3

 
19,424

 
31.5

 
8.0

Research and development expense
7,548

 
11.6

 
6,844

 
11.1

 
10.3

Interest (income)expense, net
480

 
0.7

 
348

 
0.6

 
 
Other (income)expense, net
2,743

 
4.2

 
(768
)
 
(1.2
)
 
 
Restructuring (income)expense, net
569

 
0.9

 

 

 
 
Earnings before provision for taxes on income
12,361

 
19.0

 
16,947

 
27.5

 
(27.1
)
Provision for taxes on income
2,689

 
4.1

 
3,613

 
5.8

 
(25.6
)
Net earnings
$
9,672

 
14.9

 
$
13,334

 
21.7

 
(27.5
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
$
3.49

 
 
 
$
4.78

 
 
 
(27.0
)
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,775.3

 
 
 
2,788.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
21.8
%
 
 
 
21.3
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings(A)
 
 
 
 
 
 
 
 
 
     Earnings before provision for taxes on income
$
17,353

(1)
26.7

 
$
16,830

(1)
27.3

 
3.1

     Net earnings
$
13,867

(1)
21.3

 
$
13,279

(1)
21.6

 
4.4

     Net earnings per share (Diluted)
$
5.00

(1)
 
 
$
4.76

(1)
 
 
5.0

     Effective tax rate
20.1
%
 
 
 
21.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, they may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as business development, strategic developments (including restructuring and product line changes), significant litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, merger-related or other restructuring charges, and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. See Reconciliation of Non-GAAP Measures.





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FOURTH QUARTER
 
 
 
 
 
Percent Change
 
2011
 
2010
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
$
1,248

 
1,219

 
2.4

%
2.4

 

    International
2,420

 
2,391

 
1.2

 
2.8

 
(1.6
)
 
3,668

 
3,610

 
1.6

 
2.7

 
(1.1
)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
2,887

 
3,149

 
(8.3
)
 
(8.3
)
 

    International
3,207

 
2,561

 
25.2

 
25.0

 
0.2

 
6,094

 
5,710

 
6.7

 
6.6

 
0.1

 
 
 
 
 
 
 
 
 
 
Med Devices & Diagnostics
 
 
 
 
 
 
 
 
 
    U.S.
2,850

 
2,861

 
(0.4
)
 
(0.4
)
 

    International
3,643

 
3,463

 
5.2

 
4.6

 
0.6

 
6,493

 
6,324

 
2.7

 
2.4

 
0.3

 
 
 
 
 
 
 
 
 
 
U.S.
6,985

 
7,229

 
(3.4
)
 
(3.4
)
 

International
9,270

 
8,415

 
10.2

 
10.4

 
(0.2
)
Worldwide
$
16,255

 
15,644

 
3.9

%
4.0

 
(0.1
)





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
TWELVE MONTHS
 
 
 
 
 
Percent Change
 
2011
 
2010
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
$
5,151

 
5,519

 
(6.7
)
%
(6.7
)
 

    International
9,732

 
9,071

 
7.3

 
2.9

 
4.4

 
14,883

 
14,590

 
2.0

 
(0.7
)
 
2.7

 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
12,386

 
12,519

 
(1.1
)
 
(1.1
)
 

    International
11,982

 
9,877

 
21.3

 
15.5

 
5.8

 
24,368

 
22,396

 
8.8

 
6.2

 
2.6

 
 
 
 
 
 
 
 
 
 
Med Devices & Diagnostics
 
 
 
 
 
 
 
 
 
    U.S.
11,371

 
11,412

 
(0.4
)
 
(0.4
)
 

    International
14,408

 
13,189

 
9.2

 
3.4

 
5.8

 
25,779

 
24,601

 
4.8

 
1.7

 
3.1

 
 
 
 
 
 
 
 
 
 
U.S.
28,908

 
29,450

 
(1.8
)
 
(1.8
)
 

International
36,122

 
32,137

 
12.4

 
7.0

 
5.4

Worldwide
$
65,030

 
61,587

 
5.6

%
2.8

 
2.8





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FOURTH QUARTER
 
 
 
 
 
Percent Change
 
2011
 
2010
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
$
6,985

 
7,229

 
(3.4
)
%
(3.4
)
 

 
 
 
 
 
 
 
 
 
 
Europe
4,279

 
3,947

 
8.4

 
9.4

 
(1.0
)
Western Hemisphere excluding U.S.
1,688

 
1,471

 
14.8

 
17.8

 
(3.0
)
Asia-Pacific, Africa
3,303

 
2,997

 
10.2

 
7.9

 
2.3

International
9,270

 
8,415

 
10.2

 
10.4

 
(0.2
)
 
 
 
 
 
 
 
 
 
 
Worldwide
$
16,255

 
15,644

 
3.9

%
4.0

 
(0.1
)





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
TWELVE MONTHS
 
 
 
 
 
Percent Change
 
2011
 
2010
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
$
28,908

 
29,450

 
(1.8
)
%
(1.8
)
 

 
 
 
 
 
 
 
 
 
 
Europe
17,129

 
15,510

 
10.4

 
5.3

 
5.1

Western Hemisphere excluding U.S.
6,418

 
5,550

 
15.6

 
12.2

 
3.4

Asia-Pacific, Africa
12,575

 
11,077

 
13.5

 
6.6

 
6.9

International
36,122

 
32,137

 
12.4

 
7.0

 
5.4

 
 
 
 
 
 
 
 
 
 
Worldwide
$
65,030

 
61,587

 
5.6

%
2.8

 
2.8






Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
% Change
 
 
 
2011
 
2010
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
US
 
$
103

 
103

0.0
%
0.0
%

Intl
 
 
465

 
474

(1.9
)
0.7

(2.6
)
WW
 
 
568

 
577

(1.6
)
0.6

(2.2
)
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
US
 
 
173

 
149

16.1

16.1


Intl
 
 
239

 
240

(0.4
)
1.4

(1.8
)
WW
 
 
412

 
389

5.9

7.0

(1.1
)
 
 
 
 
 
 
 
 
 
OTC/NUTRITIONALS
 
 
 
 
 
 
 
 
US
 
 
370

 
381

(2.9
)
(2.9
)

Intl
 
 
766

 
711

7.7

8.7

(1.0
)
WW
 
 
1,136

 
1,092

4.0

4.6

(0.6
)
 
 
 
 
 
 
 
 
 
SKIN CARE
 
 
 
 
 
 
 
 
US
 
 
403

 
352

14.5

14.5


Intl
 
 
541

 
537

0.7

1.3

(0.6
)
WW
 
 
944

 
889

6.2

6.6

(0.4
)
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
US
 
 
89

 
118

(24.6
)
(24.6
)

Intl
 
 
309

 
332

(6.9
)
(4.0
)
(2.9
)
WW
 
 
398

 
450

(11.6
)
(9.5
)
(2.1
)
 
 
 
 
 
 
 
 
 
WOUND CARE/OTHER
 
 
 
 
 
 
 
 
US
 
 
110

 
116

(5.2
)
(5.2
)

Intl
 
 
100

 
97

3.1

6.2

(3.1
)
WW
 
 
210

 
213

(1.4
)
(0.5
)
(0.9
)
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
US
 
 
1,248

 
1,219

2.4

2.4


Intl
 
 
2,420

 
2,391

1.2

2.8

(1.6
)
WW
 
 $
3,668

 
3,610

1.6
%
2.7
%
(1.1
)%
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
% Change
 
 
 
2011
 
2010
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACIPHEX/PARIET
 
 
 
 
 
 
 
 
US
 
 $
110

 
119

(7.6
)%
(7.6
)%

Intl
 
 
144

 
133

8.3

8.7

(0.4
)
WW
 
 
254

 
252

0.8

1.0

(0.2
)
 
 
 
 
 
 
 
 
 
CONCERTA/METHYLPHENIDATE
 
 
 
 
 
US
 
 
155

 
261

(40.6
)
(40.6
)

Intl
 
 
119

 
107

11.2

11.6

(0.4
)
WW
 
 
274

 
368

(25.5
)
(25.4
)
(0.1
)
 
 
 
 
 
 
 
 
 
DOXIL/CAELYX
 
 
 
 
 
 
 
 
US
 
 
10

 
55

(81.8
)
(81.8
)

Intl
 
 
29

 
12

             *
                             *
(10.3
)
WW
 
 
39

 
67

(41.8
)
(34.1
)
(7.7
)
 
 
 
 
 
 
 
 
 
DURAGESIC/FENTANYL TRANSDERMAL
 
 
 
 
 
US
 
 
21

 
45

(53.3
)
(53.3
)

Intl
 
 
119

 
151

(21.2
)
(21.9
)
0.7

WW
 
 
140

 
196

(28.6
)
(29.1
)
0.5

 
 
 
 
 
 
 
 
 
LEVAQUIN/FLOXIN
 
 
 
 
 
 
 
 
US
 
 
(6
)
 
386

             *
                             *

Intl
 
 
11

 
14

(21.4
)
(17.7
)
(3.7
)
WW
 
 
5

 
400

(98.8
)
(98.7
)
(0.1
)
 
 
 
 
 
 
 
 
 
PREZISTA
 
 
 
 
 
 
 
 
US
 
 
143

 
111

28.8

28.8


Intl
 
 
173

 
125

38.4

39.0

(0.6
)
WW
 
 
316

 
236

33.9

34.2

(0.3
)
 
 
 
 
 
 
 
 
 
PROCRIT/EPREX
 
 
 
 
 
 
 
 
US
 
 
191

 
270

(29.3
)
(29.3
)

Intl
 
 
177

 
209

(15.3
)
(13.7
)
(1.6
)
WW
 
 
368

 
479

(23.2
)
(22.6
)
(0.6
)
 
 
 
 
 
 
 
 
 
REMICADE
 
 
 
 
 
 
 
 
US
 
 
776

 
679

14.3

14.3


US Exports (3)
 
 
437

 
381

14.7

14.7


Intl
 
 
215

 
5

             *
                             *
2.3

WW
 
 
1,428

 
1,065

34.1

33.6

0.5

 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
% Change
 
 
 
2011
 
2010
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RISPERDAL/RISPERIDONE
 
 
 
 
 
 
 
 
US
 
$
7

 
2

              *
                              *

Intl
 
 
141

 
149

(5.4
)
(7.9
)
2.5

WW
 
 
148

 
151

(2.0
)
(4.4
)
2.4

 
 
 
 
 
 
 
 
 
RISPERDAL CONSTA
 
 
 
 
 
 
 
 
US
 
 
108

 
105

2.9

2.9


Intl
 
 
277

 
283

(2.1
)
(1.3
)
(0.8
)
WW
 
 
385

 
388

(0.8
)
(0.2
)
(0.6
)
 
 
 
 
 
 
 
 
 
TOPAMAX
 
 
 
 
 
 
 
 
US
 
 
40

 
37

8.1

8.1


Intl
 
 
81

 
84

(3.6
)
(2.6
)
(1.0
)
WW
 
 
121

 
121

0.0

0.7

(0.7
)
 
 
 
 
 
 
 
 
 
VELCADE
 
 
 
 
 
 
 
 
US
 
 

 




Intl
 
 
352

 
287

22.6

22.4

0.2

WW
 
 
352

 
287

22.6

22.4

0.2

 
 
 
 
 
 
 
 
 
OTHER
 
 
 
 
 
 
 
 
US
 
 
895

 
698

28.2

28.2


Intl
 
 
1,369

 
1,002

36.6

36.0

0.6

WW
 
 
2,264

 
1,700

33.2

32.8

0.4

 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
US
 
 
2,887

 
3,149

(8.3
)
(8.3
)

Intl
 
 
3,207

 
2,561

25.2

25.0

0.2

WW
 
 $
6,094

 
5,710

6.7
%
6.6
%
0.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
Fourth Quarter
 
 
 
 
Total
 
 
2011
2010
% Change
 
 
 
 
 
MAJOR NEW PHARMACEUTICAL PRODUCTS
(Included in Other)
 
 
 
 
 
 
 
 
 
INTELENCE
 
 
 
 
US
 
$
45

34

32.4
%
Intl
 
38

31

22.6

WW
 
83

65

27.7

 
 
 
 
 
INVEGA
 
 
 
 
US
 
66

70

(5.7
)
Intl
 
59

46

28.3

WW
 
125

116

7.8

 
 
 
 
 
SIMPONI
 
 
 
 
US
 
62

56

10.7

Intl
 
57

9

             *
WW
 
119

65

83.1

 
 
 
 
 
STELARA
 
 
 
 
US
 
126

73

72.6

Intl
 
81

47

72.3

WW
 
$
207

120

72.5
%
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
% Change
 
 
 
2011
 
2010
Reported
Operational (1)
Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR CARE (5)
 
 
 
 
 
US
 
 $
191

 
246

(22.4
)%
(22.4
)%

Intl
 
 
349

 
383

(8.9
)
(9.6
)
0.7

WW
 
 
540

 
629

(14.1
)
(14.5
)
0.4

 
 
 
 
 
 
 
 
 
DEPUY
 
 
 
 
 
 
 
 
US
 
 
775

 
807

(4.0
)
(4.0
)

Intl
 
 
678

 
640

5.9

5.7

0.2

WW
 
 
1,453

 
1,447

0.4

0.3

0.1

 
 
 
 
 
 
 
 
 
DIABETES CARE
 
 
 
 
 
 
 
 
US
 
 
330

 
318

3.8

3.8


Intl
 
 
340

 
326

4.3

4.4

(0.1
)
WW
 
 
670

 
644

4.0

4.1

(0.1
)
 
 
 
 
 
 
 
 
 
ETHICON
 
 
 
 
 
 
 
 
US
 
 
536

 
501

7.0

7.0


Intl
 
 
697

 
651

7.1

7.6

(0.5
)
WW
 
 
1,233

 
1,152

7.0

7.3

(0.3
)
 
 
 
 
 
 
 
 
 
ETHICON ENDO-SURGERY
 
 
 
 
 
 
 
 
US
 
 
524

 
501

4.6

4.6


Intl
 
 
809

 
756

7.0

6.3

0.7

WW
 
 
1,333

 
1,257

6.0

5.6

0.4

 
 
 
 
 
 
 
 
 
ORTHO-CLINICAL DIAGNOSTICS
 
 
 
US
 
 
280

 
276

1.4

1.4


Intl
 
 
274

 
260

5.4

4.8

0.6

WW
 
 
554

 
536

3.4

3.1

0.3

 
 
 
 
 
 
 
 
 
VISION CARE
 
 
 
 
 
 
 
 
US
 
 
214

 
212

0.9

0.9


Intl
 
 
496

 
447

11.0

8.2

2.8

WW
 
 
710

 
659

7.7

5.8

1.9

 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
 
 
US
 
 
2,850

 
2,861

(0.4
)
(0.4
)

Intl
 
 
3,643

 
3,463

5.2

4.6

0.6

WW
 
 $
6,493

 
6,324

2.7
 %
2.4
 %
0.3
%
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
% Change
 
 
 
2011
 
2010
Reported
Operational (1)
Currency

 
CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
US
$
418

 
409

2.2
%
2.2
 %

 
Intl
 
1,922

 
1,800

6.8

3.4

3.4

 
WW
 
2,340

 
2,209

5.9

3.2

2.7

 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
US
 
656

 
635

3.3

3.3


 
Intl
 
968

 
891

8.6

3.9

4.7

 
WW
 
1,624

 
1,526

6.4

3.6

2.8

 
 
 
 
 
 
 
 
 
 
OTC/NUTRITIONALS
 
 
 
 
 
 
 
 
US
 
1,429

 
1,853

(22.9
)
(22.9
)

 
Intl
 
2,973

 
2,696

10.3

5.2

5.1

 
WW
 
4,402

 
4,549

(3.2
)
(6.2
)
3.0

 
 
 
 
 
 
 
 
 
 
SKIN CARE
 
 
 
 
 
 
 
 
US
 
1,654

 
1,537

7.6

7.6


 
Intl
 
2,061

 
1,915

7.6

3.0

4.6

 
WW
 
3,715

 
3,452

7.6

5.0

2.6

 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
US
 
439

 
522

(15.9
)
(15.9
)

 
Intl
 
1,353

 
1,322

2.3

(1.5
)
3.8

 
WW
 
1,792

 
1,844

(2.8
)
(5.5
)
2.7

 
 
 
 
 
 
 
 
 
 
WOUND CARE/OTHER
 
 
 
 
 
 
 
 
US
 
555

 
563

(1.4
)
(1.4
)

 
Intl
 
455

 
447

1.8

(3.3
)
5.1

 
WW
 
1,010

 
1,010

0.0

(2.3
)
2.3

 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
US
 
5,151

 
5,519

(6.7
)
(6.7
)

 
Intl
 
9,732

 
9,071

7.3

2.9

4.4

 
WW
 $
14,883

 
14,590

2.0
%
(0.7
)%
2.7
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
% Change